Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment

ClinicalTrials.gov ID: NCT00623480

Public ClinicalTrials.gov record NCT00623480. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Controlled, Parallel, Prospective Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects, as Applicable, Compared to That of Episodic Treatment

Study identification

NCT ID: NCT00623480
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Bayer; Industry
Enrollment: 84 participants

Conditions and interventions

Conditions

Hemophilia A

Interventions

Recombinant Factor VIII (Kogenate FS, BAY14-2222) Biological

Biological

Eligibility (public fields only)

Age range: 12 Years to 50 Years
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 29, 2008
Primary completion: Aug 31, 2011
Completion: Oct 31, 2013
Last update posted: Nov 16, 2014

2008 – 2013

United States locations

U.S. sites: 28
U.S. states: 24
U.S. cities: 26

Facility	City	State	ZIP	Site status
Not listed	Tucson	Arizona	85724	—
Not listed	Little Rock	Arkansas	72202	—
Not listed	Orange	California	92868	—
Not listed	Sacramento	California	95817	—
Not listed	Aurora	Colorado	80045	—
Not listed	Washington D.C.	District of Columbia	20007-2197	—
Not listed	Orlando	Florida	32801	—
Not listed	Atlanta	Georgia	30322	—
Not listed	Chicago	Illinois	60611	—
Not listed	Chicago	Illinois	60612	—
Not listed	Indianapolis	Indiana	46260	—
Not listed	Iowa City	Iowa	52242-1089	—
Not listed	Louisville	Kentucky	40202	—
Not listed	Boston	Massachusetts	02115	—
Not listed	Detroit	Michigan	48201-2196	—
Not listed	Minneapolis	Minnesota	55455	—
Not listed	Kansas City	Missouri	64108	—
Not listed	Las Vegas	Nevada	89109-2803	—
Not listed	Newark	New Jersey	07112	—
Not listed	New York	New York	10029	—
Not listed	New York	New York	10065	—
Not listed	Cleveland	Ohio	44106	—
Not listed	Hershey	Pennsylvania	17033-0850	—
Not listed	Pittsburgh	Pennsylvania	15213	—
Not listed	Knoxville	Tennessee	37920	—
Not listed	Houston	Texas	77030	—
Not listed	Salt Lake City	Utah	84132	—
Not listed	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00623480, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 16, 2014 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00623480 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →